This episode expands antimicrobial thinking beyond malaria to the diverse world of protozoal infections-amebiasis, giardiasis, trichomoniasis, leishmaniasis, trypanosomiasis, and beyond. The unifying lesson is diversity: protozoa share a kingdom, not a strategy. We explore metabolic vulnerabilities, tissue tropism, intracellular sanctuaries, and host–parasite dynamics to show why drugs that cure one protozoal disease may be useless-or dangerous-in another. Pharmacology here is about specificity, staging, and clinical context.

Key takeaways to sharpen judgement:

* Diversity within similarity: why “protozoa” is not a therapeutic category.

* Tissue matters: luminal vs invasive disease changes drug choice.

* Metabolic targets: redox systems, DNA synthesis, and unique enzymes.

* Toxicity trade-offs: narrow therapeutic windows and monitoring burden.

* Strategy over speed: eradication, suppression, or control depending on disease.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe